While neuroimaging and fluid biomarkers of Aβ and tau are routinely established for AD diagnosis [2, 3], reliable prognosis of cognitive decline remains a critical challenge, which is further complicated by the considerable heterogeneity in symptom manifestation and disease progression [4–6]. The gene discussed is MAPT; the disease is Alzheimer disease.